Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The semaglutide group had increased CTX-1, with an estimated difference of 166.4 g/L (p = 0.021), and reduced BMD in the lumbar spine (ETD: -0.018 g/cm
Research focus Summary of contexts in which this compound appears in the preclinical literature
In a phase 2 clinical trial conducted on an obese population, over a 26-week period, patients who were administered a dose range of efinopegdutide from 5 mg to 10 mg experienced a weight reduction of up to 11.8%
They do not constitute claims of therapeutic efficacy or safety
US$ 22.83
US$ 22.16
US$ 25.59
US$ 24.74
US$ 23.79
US$ 20.45
US$ 22.41
US$ 23.07
